Bod says its softgel product could be the ‘benchmark delivery format’ for over-the-counter CBD by Martin Lane November 23, 2022April 29, 2024 Bod Australia has announced positive results from a Phase 1 pharmacokinetic (PK) study evaluating its ECS […]
Cann Group looks to raise another A$10m for Mildura, puts Southern facility up for sale by Martin Lane October 25, 2022April 29, 2024
Company news: Bod; Incannex; Medlab; Rua Bioscience; Emyria by Martin Lane October 20, 2022April 29, 2024
Bod spies ‘enormous potential’ of technology acquisition as pressure grows to generate revenue by Steve Jones October 13, 2022April 29, 2024
Company news: Bod Australia; Cann Group; MediCann Health; MGC Pharma; Wellnex Life by Steve Jones and Martin Lane October 5, 2022April 29, 2024
Bod reports decline in revenue and announces plan to acquire UK firm by Steve Jones September 1, 2022April 29, 2024
Company news: Bod; Neurotech International; Emyria; Creso Pharma by Martin Lane August 23, 2022April 29, 2024
Bod’s S3 registration candidate to go on sale through Special Access Scheme by Steve Jones June 27, 2022April 29, 2024
Bod prepares to launch pharma-grade CBG product in Oz and UK by Martin Lane May 26, 2022April 29, 2024
